| Literature DB >> 1893706 |
R A Wild1, L M Demers, D Applebaum-Bowden, R Lenker.
Abstract
Fifty-one hirsute women were randomly treated for nine months with ethinyl estradiol 35 ug plus norethindrone 0.4 mg or 30 ug ethinyl estradiol plus 1.5 mg norethindrone acetate if they needed contraception or spironolactone 200 mg daily if they did not. Metabolic evaluations in response to therapy demonstrated triglyceride elevations with the two oral contraceptives but not with spironolactone. While systolic blood pressure was lower with spironolactone, fasting insulin levels were higher as opposed to either low-dose oral contraceptive preparation. Ethinyl estradiol 30 ug plus 1.5 mg norethindrone acetate lowered 3-alpha-diol glucuronide levels, yet ethinyl estradiol 35 ug plus norethindrone 0.4 mg and spironolactone were more effective in lowering Ferriman-Gallwey Scores. Treatment strategies for hirsute women need to consider metabolic consequences as well as efficacy.Entities:
Keywords: Americas; Androgens; Biology; Blood Pressure; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--therapeutic use; Contraceptive Agents--administraction and dosage; Contraceptive Agents--therapeutic use; Contraceptive Methods--administraction and dosage; Contraceptive Methods--therapeutic use; Demographic Factors; Developed Countries; Diseases; Drugs--administraction and dosage; Endocrine System; Estradiol--analysis; Estrogens; Estrone--analysis; Ethinyl Estradiol--administraction and dosage; Ethinyl Estradiol--therapeutic use; Examinations And Diagnoses; Family Planning; Follicle Stimulating Hormone--analysis; Gonadotropins; Gonadotropins, Pituitary; Hemic System; Hirsutism; Hormones; Laboratory Examinations And Diagnoses; Luteinizing Hormone--analysis; Metabolic Effects; Norethindrone--administraction and dosage; Norethindrone--therapeutic use; North America; Northern America; Oral Contraceptives, Low-dose--administraction and dosage; Oral Contraceptives, Low-dose--therapeutic use; Oral Contraceptives--administraction and dosage; Oral Contraceptives--therapeutic use; Pennsylvania; Physiology; Population; Population Characteristics; Signs And Symptoms; Steroid Metabolic Effects; Testosterone--analysis; Treatment; United States
Mesh：
Substances：
Year: 1991 PMID： 1893706 DOI： 10.1016/0010-7824(91)90112-s
Source DB: PubMed Journal: Contraception ISSN： 0010-7824 Impact factor: 3.375